MX2020003001A - Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. - Google Patents

Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.

Info

Publication number
MX2020003001A
MX2020003001A MX2020003001A MX2020003001A MX2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A
Authority
MX
Mexico
Prior art keywords
water
roflumilast
miscible
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
MX2020003001A
Other languages
English (en)
Inventor
David W Osborne
Original Assignee
Arcutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcutis Inc filed Critical Arcutis Inc
Publication of MX2020003001A publication Critical patent/MX2020003001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La baja solubilidad acuosa de roflumilast en preparaciones parenterales y emulsiones tópicas, suspensiones, geles o soluciones se puede mejorar al incluir una mezcla de solventes miscibles en agua en la composición farmacéutica; la mezcla de solventes miscibles en agua puede incluir dietilen glicol monoetil éter (Nombre comercial Transcutol(r); abreviado DEGEE) y agua; la relación de dietilen glicol monoetil éter a agua es de 1:10 a 20:1; la composición resultante tiene biodisponibilidad y eficacia mejoradas y se puede utilizar para inhibir la fosfodiesterasa 4 en un paciente en necesidad de dicho tratamiento.
MX2020003001A 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. MX2020003001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,900 US11534493B2 (en) 2017-09-22 2017-09-22 Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
PCT/US2018/051691 WO2019060379A1 (en) 2017-09-22 2018-09-19 PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE SOLVENTS MISCIBLE TO WATER

Publications (1)

Publication Number Publication Date
MX2020003001A true MX2020003001A (es) 2020-09-28

Family

ID=63794682

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003001A MX2020003001A (es) 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.
MX2023011557A MX2023011557A (es) 2017-09-22 2020-03-18 Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011557A MX2023011557A (es) 2017-09-22 2020-03-18 Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables.

Country Status (13)

Country Link
US (2) US11534493B2 (es)
EP (2) EP3684334B1 (es)
JP (3) JP7191944B2 (es)
KR (1) KR102681877B1 (es)
CN (1) CN111107836A (es)
AU (1) AU2018337752B2 (es)
BR (1) BR112020005421A8 (es)
CA (1) CA3076002A1 (es)
EA (1) EA202090813A1 (es)
ES (1) ES2972843T3 (es)
IL (1) IL273376B2 (es)
MX (2) MX2020003001A (es)
WO (1) WO2019060379A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
KR20210044191A (ko) 2018-06-04 2021-04-22 아큐티스, 인크. 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
CN114828840A (zh) * 2019-10-11 2022-07-29 泽威恩制药有限责任公司 秋水仙碱的改进的局部用组合物
MX2022009399A (es) * 2020-01-31 2022-09-19 Arcutis Biotherapeutics Inc Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
WO2022169615A1 (en) * 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2259692A (en) * 1991-07-03 1993-02-11 Sano Corporation Composition and method for transdermal delivery of diclofenac
KR100331255B1 (ko) 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
GB9618974D0 (en) * 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CN101491520B (zh) 2002-05-28 2011-03-16 尼科梅德有限责任公司 局部应用的药物制剂
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
CN101541321A (zh) * 2006-09-06 2009-09-23 Isw集团公司 局部用组合物
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
US20120252793A1 (en) 2011-03-31 2012-10-04 Gary Bream Intranasal benzodiazepine pharmaceutical compositions
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
DK2704703T3 (da) * 2011-05-03 2019-10-14 Aponia Laboratories Inc Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
EP3763366A1 (en) 2013-01-28 2021-01-13 Incozen Therapeutics Pvt. Ltd. Roflumilast n-oxide for use in treating autoimmune, respiratory and inflammatory disorders by inhalation
US20140275265A1 (en) * 2013-03-12 2014-09-18 Core Products International, Inc. Therapeutic cream for application to skin
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
BR112017004032A2 (pt) * 2014-08-27 2017-12-05 Abbvie Inc formulação tópica
KR102106230B1 (ko) 2015-11-30 2020-04-29 아나코르 파마슈티칼스 인코포레이티드 염증성-관련 상태를 치료하기 위한 국소 제약 제제
CN109310624A (zh) * 2016-06-15 2019-02-05 托伦特药物有限公司 阿普斯特的局部组合物
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast

Also Published As

Publication number Publication date
EA202090813A1 (ru) 2020-08-14
IL273376B2 (en) 2024-07-01
IL273376B1 (en) 2024-03-01
US20230091358A1 (en) 2023-03-23
US20190091333A1 (en) 2019-03-28
WO2019060379A1 (en) 2019-03-28
JP2024028911A (ja) 2024-03-05
EP4316590A3 (en) 2024-05-01
EP3684334C0 (en) 2023-12-06
AU2018337752B2 (en) 2024-03-28
JP2020534303A (ja) 2020-11-26
MX2023011557A (es) 2023-10-09
EP3684334A1 (en) 2020-07-29
ES2972843T3 (es) 2024-06-17
EP4316590A2 (en) 2024-02-07
CA3076002A1 (en) 2019-03-28
KR102681877B1 (ko) 2024-07-04
JP7402301B2 (ja) 2023-12-20
CN111107836A (zh) 2020-05-05
JP7191944B2 (ja) 2022-12-19
JP2023027195A (ja) 2023-03-01
EP3684334B1 (en) 2023-12-06
US11534493B2 (en) 2022-12-27
BR112020005421A2 (pt) 2020-09-29
IL273376A (en) 2020-05-31
AU2018337752A1 (en) 2020-04-09
KR20200058402A (ko) 2020-05-27
BR112020005421A8 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
MX2023011557A (es) Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MY187047A (en) Selective pyy compounds and uses thereof
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
WO2015120231A3 (en) Stable peptide formulations and methods for preparation
EA201600118A1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
TN2015000445A1 (en) Derivatives of dolastatin 10 and auristatins
MY179605A (en) Use of benzimidazole-proline derivatives
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2013007909A (es) Formulaciones inmunosupresoras.
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
SA521430973B1 (ar) صيغ علاجية ثابتة في مذيبات قطبية غير بروتونية وطرق لتصنيعها
EA202090445A1 (ru) ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MY198473A (en) Glucono delta-lactone for treatment of vaginal fungal infections
MX2019004576A (es) Composiciones farmaceuticas.
RU2017129736A (ru) Не окрашивающая гелевая композиция, содержащая нимесулид, для местного применения
WO2019166033A3 (zh) 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途
MX2019010618A (es) Composicion farmacéutica oftálmica, procesos de preparación y usos de las mismas.
MX2021000403A (es) Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.